Phase III success with anthrax vaccine in post-exposure prophylaxis
This article was originally published in Scrip
Executive Summary
A pivotal Phase III study of Emergent BioSolutions' anthrax vaccine BioThrax for post-exposure prophylaxis (PEP) has met its primary and key secondary endpoints.